Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemia

By Prescott Hillary   Kantarjian Hagop   Cortes Jorge   Ravandi Farhad  

Expert Opinion on Emerging Drugs, Vol. 16, Iss. 3, 2011-09 ,pp. : 407-423

Informa Healthcare

Access to resources Recommend Favorite

Soluble fms-like tyrosine kinase-1 antibody for diagnosis purposes (WO2010075475)

By Boyaud France   Inguimbert Nicolas  

Expert Opinion on Therapeutic Patents, Vol. 21, Iss. 6, 2011-06 ,pp. : 971-975

Informa Healthcare

Access to resources Recommend Favorite

Spleen tyrosine kinase inhibitors: a review of the patent literature 2010 – 2013

By Norman Peter  

Expert Opinion on Therapeutic Patents, Vol. 24, Iss. 5, 2014-05 ,pp. : 573-595

Informa Healthcare

Access to resources Recommend Favorite

Phosphoinositide 3-kinase α inhibitors: a patent review

By Denny William A  

Expert Opinion on Therapeutic Patents, Vol. 23, Iss. 7, 2013-07 ,pp. : 789-799

Informa Healthcare

Access to resources Recommend Favorite

Nutraceutical Targeting of Placental Synthesis of Soluble Fms-Like Tyrosine Kinase- 1 (sFlt-1) as Strategy for Preventing and Controlling Pre-eclampsia

By  

Current Pharmaceutical Design, Vol. 24, Iss. 20, 2018-06 ,pp. : 2255-2263

Bentham Science Publishers

Access to resources Recommend Favorite